The firm recorded Q4 oncology revenues of $4.06 billion compared to $3.19 billion in the same period last year.
Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...
Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...
U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by cost-cutting efforts and ...
In 2000, the Union for International Cancer Control (UICC) named Feb. | In 2000, the Union for International Cancer Control named Feb. 4 World Cancer Day, with a goal of raising awareness of cancer ...
Pfizer has taken a $1.2 billion hit after reassessing the prospects of two antibody-drug conjugates (ADC) it picked up in the ...
The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...
Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...
CNW/ - This World Cancer Day, Pfizer Canada ULC, together with Rethink Breast Cancer, Colorectal Cancer Canada, Lung Health Foundation, Lung Cancer Canada, and the Quebec Lung Association, is pleased ...
CARLSBAD, Calif. - Tyra Biosciences , Inc. (NASDAQ:TYRA), a biotech firm specializing in precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, today announced the appointment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback